|
Press Releases |
|
|
|
Friday, May 29, 2020 |
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
Monday, May 18, 2020 |
|
エーザイ、「新セルベール(R)整胃プレミアム<錠>」「新セルベール(R)整胃プレミアム<細粒>」新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、弱ってきた胃を粘液のベールで守り整える「セルベール」ブランドから、「新セルベール(R)整胃プレミアム<錠>」および「新セルベール(R)整胃プレミアム<細粒>」(いずれも第 2 類医薬品、以下 「新セルベール整胃プレミアム」)を本日、5 月 18 日(月)に全国の薬局・薬店、ドラッグストアにて新発売します。 more info >> |
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
Thursday, May 14, 2020 |
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の開発品・製品に関する演題について |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、2020年5月29日-31日に開催される「米国臨床腫瘍学会(American Society of Clinical Oncology:ASCO)年次総会」(ASCO20 Virtual Scientific Program*)において、当社が創製したレンバチニブメシル酸塩(マルチキナーゼ阻害剤、製品名:「レンビマ(R)」、以下 レンバチニブ)、エリブリンメシル酸塩(ハリコンドリン系微小管ダイナミクス阻害剤、製品名:「ハラヴェン(R)」、以下 エリブリン)に関する最新知見を発表することをお知らせします。 more info >> |
|
Tuesday, April 28, 2020 |
|
エーザイ、Institutional Investor誌の「The All-Japan Executive Team」において、「Most Honored Company」およびセクター第1位に選出 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、米国金融情報誌「Institutional Investor」がこのたび発表した「The All-Japan Executive Team」のBiotechnology & Pharmaceuticalsセクターにおいて、「Best CEOs」「Best CFOs」でそれぞれ第1位となり、「Most Honored Company」およびセクター総合第1位に選定されたことをお知らせします。 more info >> |
|
Monday, April 27, 2020 |
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
Thursday, April 2, 2020 |
|
エーザイと生化学工業、変形性関節症治療剤SI-613について中国における共同開発及び販売提携に関する契約を締結 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫、以下 エーザイ)と生化学工業株式会社(本社:東京都、代表取締役社長:水谷建、以下 生化学工業)は、このたび、生化学工業が創出した変形性関節症治療剤 SI-613(ジクロフェナク結合ヒアルロン酸)について、中国における共同開発及び販売提携に関する契約を締結しましたのでお知らせします。 more info >> |
|
Wednesday, April 1, 2020 |
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
Thursday, March 26, 2020 |
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Kaplan Fox & Kilsheimer LLP is Investigating DexCom, Inc. (DXCM) for Potential Securities Law Violations
Jul 27, 2024 18:00 HKT/SGT
|
|
|
SMG Deadline to Lead in Securities Fraud Lawsuit is August 5, 2024 - Contact Kaplan Fox & Kilsheimer LLP
Jul 27, 2024 18:00 HKT/SGT
|
|
|
Funimation Founder, Gen Fukunaga, Joins as Investor and Advisor to Toonsutra, India's #1 Webtoon App
Jul 27, 2024 17:00 HKT/SGT
|
|
|
Domino's Pizza Inc. Is Being Investigated by Kaplan Fox & Kilsheimer LLP for Potential Securities Law Violations
Jul 26, 2024 23:30 HKT/SGT
|
|
|
VCI Global Enters into AI Computing Alliance (AICA) Led by Enlight Corporation and Supermicro
Jul 26, 2024 21:00: JST
|
|
|
CORRECTION FROM SOURCE: Doubleview Reports Maiden Mineral Resource Estimate
Jul 26, 2024 21:00 HKT/SGT
|
|
|
CITIC Resources Announces its 2024 Interim Results
Jul 26, 2024 20:43 HKT/SGT
|
|
|
中信資源公布2024年度中期業績 收入大幅增長93.1%至約39.4億港元
Jul 26, 2024 20:29 HKT/SGT
|
|
|
OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
Jul 26, 2024 20:05 HKT/SGT
|
|
|
VCI Global Enters into AI Computing Alliance (AICA) Led by Enlight Corporation and Supermicro
Jul 26, 2024 20:00 HKT/SGT
|
|
|
中信资源公布2024年度中期业绩 收入大幅增长93.1%至约39.4亿港元
Jul 26, 2024 19:57 HKT/SGT
|
|
|
華邦科技集團成員及策略夥伴攬獲「專業金融機構服務大獎2024」兩項殊榮 [更新版]
Jul 26, 2024 17:42 HKT/SGT
|
|
|
华邦科技集团成员及策略伙伴揽获“专业金融机构服务大奖2024”两项殊荣[更新版]
Jul 26, 2024 17:18 HKT/SGT
|
|
|
DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology
Jul 26, 2024 17:05 JST
|
|
|
Kucingko Berhad Debuts on ACE Market with Clawsome Opening Price of RM0.805
Jul 26, 2024 15:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|